# Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

> **NCT01804530** · PHASE1 · TERMINATED · sponsor: **Plexxikon** · enrollment: 59 (actual)

## Conditions studied

- Solid Tumor
- Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
- Tenosynovial Giant Cell Tumor

## Interventions

- **DRUG:** PLX7486 TsOH

## Key facts

- **NCT ID:** NCT01804530
- **Lead sponsor:** Plexxikon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2018-01-24
- **Final completion:** 2018-01-24
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Discontinued
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01804530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01804530, "Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01804530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*